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altered the potential of isolated cells;
or affected their gene expression com-
pared to the lung environment. More
precise analysis to rule out the possi-
bility of nonspecific lung cell marker
expression should be done, as well
as a functional analysis of individual,
freshly isolated cells. If MAPK14 is
required for lung tissue renewal as
proposed, Mapk14 mutant mice
should not be able to repair epithelial
cells after lung injury is invoked; such
experiments remain to be performed.
With the important implications for
lung stem cell biology raised by the
work of Ventura et al. (2007), and as
more studies of BASCs and/or other
lung stem/progenitor cells emerge, it
is crucial that the interpretations are
based on rigorous examination of
self-renewal and differentiation both
in vivo and in vitro. By combining
knowledge gained from these new
publications, important follow-up
work, and new distinct studies that
will emerge, it will become possible
for us to create a lineagemap that links
lung stem cells, progenitor cells, and
differentiated cells with the networks
that regulate their function.As the inter-
esting studies highlighted here show,
MAPK14 may help to map out a better
understanding of lung cell biology.
ACKNOWLEDGMENTS
The author thanks Juan Jose´ Ventura for clari-
fication of experimental approaches as well as
Genevieve Kruger, Nathan Young, and Sima
Zacharek for critical reading of the manuscript.
REFERENCES
Basseres, D.S., Levantini, E., Ji, H., Monti, S.,
Elf, S., Dayaram, T., Fenyus, M., Kocher, O.,
Golub, T., Wong, K.K., et al. (2006). Mol. Cell.
Biol. 26, 1109–1123.
Engel, F.B., Schebesta, M., Duong, M.T., Lu,
G., Ren, S., Madwed, J.B., Jiang, H., Wang,
Y., and Keating, M.T. (2005). Genes Dev. 19,
1175–1187.
Hui, L., Bakiri, L., Mairhorfer, A., Schweifer, N.,
Haslinger, C., Kenner, L., Komnenovic, V.,
Scheuch, H., Beug, H., and Wagner, E.F.
(2007). Nat. Genet., in press. Published online
April 29, 2007. 10.1038/ng2033.
Kim, C.F., Jackson, E.L., Woolfenden, A.E.,
Lawrence, S., Babar, I., Vogel, S., Crowley,
D., Bronson, R.T., and Jacks, T. (2005). Cell
121, 823–835.
Rawlins, E.L., and Hogan, B.L. (2006). Devel-
opment 133, 2455–2465.
Ventura, J.J., Tenbaum, S., Perdiguero, E.,
Huth, M., Guerra, C., Barbacid, M., Paspara-
kis, M., and Nebreda, A.R. (2007). Nat. Genet.,
in press. Published online April 29, 2007.
10.1038/ng2037.
Cell Stem Cell
PreviewsIs Ewing’s Sarcoma a Stem Cell Tumor?
Paul S. Meltzer1,*
1Genetics Branch, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Bethesda MD 20892, USA
*Correspondence: pmeltzer@mail.nih.gov
DOI 10.1016/j.stem.2007.05.011
Solving the histogenesis of Ewing’s sarcoma has defied investigators despite progress in under-
standing its molecular pathogenesis. In a recent issue of Cancer Cell, Tirode et al. (2007) present
evidence supporting the hypothesis that this rare cancer arises from a primitive mesenchymal
precursor.One of the fundamental problems of
cancer research is the identification
of the progenitor cell that gives rise to
a clinically apparent tumor. For com-
mon epithelial cancers, such as breast
and colon cancers, the problem can
be narrowed to the cell types and
stages of differentiation that occur
within the target organ. Some cancers
that are anatomically more diverse,
such as melanoma, can be tracked
back to cells of a particular develop-
mental lineage, in that case to the neu-
ral crest. Pinning down the progenitor
cell in those diseases is tricky enough
but that seems simple compared tothe problem posed by a number of
rare cancers, mostly sarcomas, that
may occur in a variety of anatomic
sites and therefore do not necessarily
declare their origin by arising from
a particular tissue (Helman and Melt-
zer, 2003). One of the greatest puzzles
has been Ewing’s sarcoma, named
after the pathologist James Ewing
whose work helped to define this en-
tity. In a recent paper in Cancer Cell,
Delattre and colleagues place one
possible piece in this puzzle (Tirode
et al., 2007).
Ewing’s sarcoma is a rare tumor that
mainly occurs in children and youngCell Stemadults. Despite progress in treating
this disease, it has a high propensity
to metastasize and remains lethal in
a substantial fraction of patients. Al-
though Ewing’s sarcoma frequently
appears to arise in bones, this is not
always the case, as there are clearly
extraosseous tumors. Moreover, it
does not typically express morpholog-
ical or biochemical markers sugges-
tive of bone differentiation. The tumors
are typically described as composed
of ‘‘small round blue cells’’ that may
express neural markers but do not
otherwise exhibit features that place
them clearly in any developmentalCell 1, July 2007 ª2007 Elsevier Inc. 13
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question of whether these anatomi-
cally diverse variants of Ewing’s sar-
coma represented one disease until it
was discovered that Ewing’s sarcoma
is characterized by specific chromo-
some translocations exemplified by
the t(11;22)(q24;q12). At the molecular
level, this translocationcreatesa fusion
gene encoding a chimeric oncoprotein
containing segments of two nuclear
proteins: EWS (EWSR1) and the ets
family transcription factor FLI1
(Delattre et al., 1992). This discovery
allowed objective classification of
anatomically diverse tumors into the
Ewing’s sarcoma family of tumors
(ESFT).
Although discovery of the EWS-FLI1
fusion was a tremendous advance for
ESFT research, it did not solve the pro-
genitor cell problem. When large-scale
expression profiling became possible,
it seemed likely that an expression sig-
nature for ESFT would finally reveal its
histogenesis. In fact, molecular diag-
nosis has enabled expression profiling
of confirmed ESFT cases, but the pro-
genitor cell was not readily identified
from those data. ESFT has a very dis-
tinctive expression signature, but this
does not cleanly map to a single well-
characterized cell lineage (Baird
et al., 2005). Two possibilities, which
are not necessarily mutually exclusive,
may be responsible for this conun-
drum. First, the EWS-FLI1 fusion
gene, acting as a transcription factor,
may perturb gene expression in the
progenitor cell, masking the original
expression signature of that cell in
ESFT tumors. Second, the ESFT
progenitor cell itself may be relatively
undifferentiated and difficult to char-
acterize. Because ESFT tumors can
occur in many bone and soft tissue
locations, the possibility emerges that
a relatively undifferentiated cell popu-
lation located diffusely in connective
tissue sites is susceptible to the trans-
forming activity of EWS-FLI1.
Against this background, a recent
study by Tirode et al. provides evi-
dence supporting the possibility that
ESFT may be derived from mesenchy-
mal stem cells (MSCs) (Tirode et al.,
2007). MSCs can be loosely defined
as cells derived from either bone mar-
row or soft tissue (e.g., muscle or14 Cell Stem Cell 1, July 2007 ª2007 Elsadipose tissue) that retain the ability
to differentiate along a number of
connective tissue lineages (adipocyte,
muscle, tendon, bone, or cartilage) (for
review see Kolf et al. [2007]). Although
it is the potential of these cells for use
in the new field of ‘‘regenerative medi-
cine’’ that has commanded the most
attention, they have also attracted the
interest of sarcoma researchers. Cell
preparations have been designated
differently by the investigators who
have developed culture protocols
(and they may indeed differ biologi-
cally), but for the sake of the present
discussion, we will lump them under
the MSC designation. Previous work
had demonstrated that, whereas
most nontumorigenic cells in culture
are unable to tolerate expression of
EWS-FLI1 without undergoing cell
cycle arrest, murine MSCs (derived
from either bone or bonemarrow) con-
tinue to proliferate after introduction of
EWS-FLI1, and their derivatives can
generate ESFT-like tumors (Castil-
lero-Trejo et al., 2005; Riggi et al.,
2005). Tirode et al. have revealed a po-
tential relationship between ESFT and
MSCs by investigating the effect of si-
lencing EWS-FLI1 on gene expression
and the biological properties of ESFT
cells. They generated expression
data from ESFT cells after silencing
EWS-FLI1 and found that the gene ex-
pression profiles shifted toward those
of two types of MSC cultures.
Changes included increased expres-
sion of several genes often expressed
in various MSC cultures. Additionally,
a number of neural genes characteris-
tically expressed in ESFT were down-
regulated after EWS-FLI1 silencing.
These results suggest that EWS-FLI1
does indeed perturb the expression
of the ESFT progenitor, leading to
loss of markers that may be expressed
in the original progenitor and aberrant
expression of markers that are nor-
mally absent in the progenitor cells.
In addition to these changes in gene
expression, Tirode et al. observed
changes in the phenotype of ES cells
after silencing EWS-FLI1 expression.
Strikingly, likeMSCs, the silenced cells
could be induced to differentiate along
osteogenic or adipogenic lineages
more readily than control cells. This
result nicely parallels studies thatevier Inc.show that introduction of EWS-FLI1
into MSCs blocks their differentiation
(Torchia et al., 2003). These observa-
tions are consistent with the MSC-
like expression signature found after
EWS-FLI1 knockdown and suggest
that silencing EWS-FLI1 causes at
least some ESFT cell lines to exhibit
MSC-like properties.
How close does the study of Tirode
et al. (2007) come to establishing that
ESFT arises from an MSC progenitor?
Some difficult problems still remain.
First and foremost, MSCs are defined
by their biological properties, particu-
larly their pluripotentiality. Unlike he-
matopoietic stem cells or embryonic
stem cells, there is no widely accepted
panel of markers for theMSC. The cur-
rent state of knowledge regarding the
MSC limits the ability to assign a role
for this cell compartment in cancer,
although like the hematopoietic stem
cell, which appears to be the progeni-
tor for some forms of leukemia, an
MSC-like cell is an attractive candi-
date for ESFT and perhaps other
sarcomas. Perhaps more extensive
comparisons between ESFT cells and
various MSC preparations would help
to solidify this issue. Additionally,
cultures of glioblastoma, a cancer of
neuroectodermal origin, have also
been induced to differentiate along
adipocyte or other mesenchymal line-
ages, perhaps reflecting a relationship
between neural stem cells and MSCs
(Tso et al., 2006). No premalignant
precursor of ESFT has been observed
in humans. Because of this limitation
and the rarity of ESFT, a faithful murine
model of ESFT made by targeting
EWS-FLI1 expression to the putative
progenitor cell would go a long way
toward enabling investigators in this
field to place the origins of ESFT on
a firm biological basis.
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in vitro and in vivo. They find a pr
during development that, surpris
If stem cells didn’t exist, we would
have to invent them. But how? We
would invent a class of proteins that
would prevent any ‘‘major’’ change in
the state of the cells as they divide.
That sounds simple, but in fact it’s
very hard to stop epigenetic modifica-
tion in its tracks. It’s like being halfway
down a double black diamond ski
slope: you must ski.
In Fasano et al., we learn that the
polycomb gene Bmi-1 first has effects
on stem cell maintenance during mid-
gestation brain development but then
has a progressively more important
role as development proceeds (Fa-
sano et al., 2007). So, in effect, Bmi-1
expression may limit the severity of
the slope that the stem cells have to
navigate. Bmi-1 is a polycomb gene
that sustains stem cells in postnatal
life. It is the mouse homolog of the fly
gene posterior sex combs (Psc) and
is a central component of polycomb
repressor complex 2 (PRC2) that
maintains chromatin in the repressed
or inactive state. Null mutant mice
show transformation of skeletal struc-
tures to more posterior identities (van
der Lugt et al., 1994). Bmi-1/ ani-
mals are born but show a decrease in
the number of hematopoietic stemRiggi, N., Cironi, L., Provero, P., Suva, M.L.,
Kaloulis, K., Garcia-Echeverria, C., Hoffmann,
F., Trumpp, A., and Stamenkovic, I. (2005).
Cancer Res. 65, 11459–11468.
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sano et al. (2007) investigate the r
ogressively increasing requiremen
ingly, seems to involve regulation
cells (HSCs) that becomes worse
with age, and the HSCs they do have
show suboptimal proliferative re-
sponses. The initially reported neuro-
logical abnormalities have been pur-
sued in studies showing that
expansion of neurospheres is compro-
mised in cells derived from late stages
of neural development (Molofsky et al.,
2003). Now, Fasano and colleagues
have used acute shRNA-mediated
knockdown to investigate the role of
Bmi-1 in a temporally regulated way.
They found that loss of Bmi-1 leads
to impaired neural stem cell prolifera-
tion, and that the strength of the effect
increases during the course of devel-
opment.
Bmi-1 was discovered as an onco-
gene, and an important paper sug-
gested that its oncogenic function is
mediated by inhibition of the Ink4a/
ARF locus (Jacobs et al., 1999). This
locus codes for two tumor suppres-
sors that act through p53 and Rb to
regulate cell-cycle progression, and
this pathway is now accepted as the
oncogenic mechanism of Bmi-1. Pre-
vious studies have implicated
p16Ink4a in mediating the effects of
Bmi-1 loss in neural stem cells (Molof-
sky et al., 2003). A reasonable predic-
Cell StemTorchia, E.C., Jaishankar, S., and Baker, S.J.
(2003). Cancer Res. 63, 3464–3468.
Tso, C.L., Shintaku, P., Chen, J., Liu, Q., Liu, J.,
Chen, Z., Yoshimoto, K., Mischel, P.S.,
Cloughesy, T.F., Liau, L.M., and Nelson, S.F.
(2006). Mol. Cancer Res. 4, 607–619.ole of Bmi-1 in neural stem cells
t for Bmi-1 function in stem cells
of the cell-cycle inhibitor p21.
tion, therefore, would have been that
the reduced proliferation seen by Fa-
sano et al. after acute Bmi-1 knock-
down is also mediated by Ink4a/ARF.
However, instead the authors saw up-
regulation of a different cell-cycle in-
hibitor, p21. Functional experiments
confirmed that reduction of p21 ex-
pression, but not of Ink4a/ARF, res-
cued the effect of losing Bmi-1. Thus,
their studies suggest that p21 rather
than Ink4a/ARF expression is the im-
mediate target of Bmi-1 in the devel-
oping CNS. Fasano et al. also noted
upregulation of other p21-Rb pathway
components in a stage-specific man-
ner. An important caveat is that the
shRNA method used could leave suffi-
cient residual expression of Ink4a/ARF
to mask a functional role in this
context. Nevertheless, this result is
important because it provides a new
molecular target to help define
the mechanisms that control progres-
sive change in stem cells during
development.
Loss of p21 or p53 leads to a long-
term loss of stem cells in the CNS
that is thought to be a consequence
of overproliferation and subsequent
exhaustion of the stem cell reservoir
(Meletis et al., 2006; Kippin et al.,
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